Scientific Advances
Natural compound speeds bone growth
Astronomers spy massive stars in the making
Frog gene map a leap forward for humans
Sun-shy mums may raise MS risk in babies
Soft fossils provide new target for ET search
Mammoth blood brought back to life
Outdoor exercise can boost self esteem
Athletes on growth hormone 'sprint faster'
Countdown begins to 520 day 'Mars mission'
Warmer planet to stress humans: study
Plasma rocket to shorten space voyages
Vaccine may trigger infant epilepsy onset
'Fingerprinting' points to dusty Australia
The hole in the ozone layer: 25 years on
Humans interbred with Neanderthals: analysis
Herschel shows star formation is slowing
Washing hands makes tough choices easier
'Face-book' to measure pain in mice
Science gives clues to World Cup success
Human sigh acts as a reset button
Expert confirms Phar Lap arsenic theory
Dictionary blunder a matter of gravity
Warning on high-dose vitamin D
Calling mum makes you feel better
Hepatitis C no longer 'death sentence'
A cure for hepatitis C should soon be possible for most patients with the virus, an expert predicts, but unless treatment uptake skyrockets, many will miss out.

Infectious diseases physician Associate Professor Joe Torresi from Melbourne's Austin Hospital Department of Infectious Diseases says emerging treatments could boost overall cure rates to as high as 95%.

Torresi will speak at the Australasian Society for Infectious Diseases annual meeting being held in Darwin this week.

"Combination antiviral therapy of pegylated interferon-a and ribavirin has become the standard of care for patients with chronic hepatitis C, and it is now possible to achieve high cure rates with this therapy," he says.

"However with the advent of direct acting antivirals and various immunotherapeutic approaches it should become possible in the future to achieve a cure in almost all patients infected with hepatitis C."

Torresi says cure rates depend on the strain or genotype. In Australia half of those infected have genotype 1, and one-third have genotypes 2 or 3, with the rest type 4 or other strains.

Treatment for 24 weeks achieves cure, defined as sustained virological response or SVR, in up to 85% of type 2 and 3 cases, while 48 weeks treatment cures between 40 and 50% of type 1 cases. But type 1 patients who have a rapid response four weeks into therapy have a cure rate up to 80% and for types 2 and 3, it is 95%.

Torresi says direct acting antivirals target a different part of the virus, preventing replication, but are not yet commercially available.

"They will probably be added to existing treatments for genotype 1 infected patients. Clinical trials [funded by drug companies] for two of them - Telaprevir and Boceprivir - found they boost SVR in those with type 1 from between 40% and 50% to 60% and 70%," he says.

"Many different types of these treatments are being developed including immunotherapetic treatments such as vaccines and drugs to block the entry of the virus into liver cells.

"Using a number of different classes of drugs in combination we hope would cure almost all of those infected and lift genotype 1 cure rates to those of genotype 2 and 3.

"If direct acting antivirals do translate to a 20% to 25% increase in SVR for genotype 1 patients, as indicated in initial clinical trials, we can expect to cure 75% to 95% of patients with hepatitis C overall."

The Austin Hospital is currently conducting clinical trials of combination therapies for hepatitis, which involves Torresi as co-investigator, along with a number of specialist gastroenterologists and hepatologists. He says he has no connection to the drug companies and does not receive funding from them.
Low treatment rates

Physician and epidemiologist Dr Benjamin Cowie from the Victorian Infectious Diseases Service, who will also speak at the conference, says without a substantial increase in the proportion of those infected receiving treatment, mortality will continue to escalate.

According to a new report by the National Centre in HIV Epidemiology and Clinical Research, only 10% of those with hepatitis C in Australia have received treatment, and just 2% are currently undergoing therapy.

A separate report, the 3rd National Hepatitis C Strategy 2010-2013 endorsed by the Federal Government, says while 284,000 Australians have been exposed to hepatitis C, some have been cured or spontaneously cleared the virus. Of the remaining 212,000 who currently have chronic hepatitis C, between 40,000 and 50,000 are undiagnosed cases.

It adds, only 3500 a year are undergoing treatment, despite 10,000 new infections and 330 deaths occurring annually, a number which is expected to start rising sharply.
Brighter future

Despite the numbers, the strategy also highlights the improvements in treating hepatitis.

"It is possible the new agents will be approved, potentially shorten treatment duration and improve response rates," says the report.

Cowie agrees that in the future it may be possible to cure most cases.

"It could happen soon because the rate of change in therapies for hepatitis C and B has been profound," he says. "A substantial proportion of those infected [with hepatitis C] can't tolerate existing drugs or they don't clear the virus. But indications are some of the new agents may enhance abilities to cure the virus."

He says one in four spontaneously clear the virus after infection but most develop chronic hepatitis, which if untreated may progress to potentially fatal cirrhosis, liver cancer or liver failure.

Cowie says side-effects and 'clinic waits' may deter some from seeking treatment. Torresi believes many think it is a death sentence, but once clinicians counsel patients about their treatment and the chance of cure, they generally stick with it.

Hepatitis C is a blood borne virus, mainly transmitted by sharing drug injecting equipment.

Transmission can also occur via non-sterile tattooing and body piercing, unsterile medical or dental procedures, from mother to infant during delivery, via needlestick injuries or exposure to blood or blood product.

Climate change impact on malaria questioned
Single lens glasses can help prevent falls
Movies manipulate our primal response
Luminescent sharks become invisible
Synthetic biology research gets a hearing
Source of ancient carbon 'burp' detected
Why the goddess of love is in a spin
Computer program recognises online sarcasm
New dinosaur had record-sized horns
Physicists solve missing neutrino mystery
Milk from grass-fed cows may be better
Crabs caught spying on rivals' love claws
Lifestyle may not boost breast cancer gene risk
'Trade-off' gene for plants discovered
Pacific islands growing, not sinking
Caffeine addicts get no real perk
Velvet worm's deadly slime revealed
SpaceX cleared for Florida lift-off
Cyborg rights 'need debating now'
Sunlight shines on silver technology
Mountain biking as risky as football, diving
Dusty simulations may reveal planets
Legal fight over breast cancer gene
Unions call for urgent nano information
Solar panel attraction deadly for insects
Meat eaters munched many ways: study
Snakes may be in decline worldwide
Dogs dumbed down by domestication
Fossil sheds new light on 'dino-bird'
DNA 'spiderbot' is on the prowl
GM cotton use increases fruit pest problem
Warming to kill off a fifth of all lizards
Super massive black hole given the boot
Ball lightning could be 'all in the mind'
Immune system could be used to test for TB
Mobile phone cancer link unclear, study
Teen brain wired to take risks
Synchrotron probes Egyptian beads
Argonauts 'gulp' air to swim freely
Space station gets a new room
'Digital genome' to protect dying data formats
Sweep yields leads for new malaria drugs
Researchers snap signs of illegal fishing
Spectrum reveals supernova surprise
Scientists create synthetic life
Eavesdropping a waste of energy
Star caught eating its offspring
Megafauna die-off may have cooled planet
Hepatitis C no longer 'death sentence'
Atoms bring quantum computing closer
Visualisation staves off constant craving
Experts debate homeopathy funding
Visit Statistics